This paper is in the following e-collection/theme issue:

Recruitment of Research Participants (277) Neurology and Neurosciences (148) Chronic Conditions (213) Research Infrastructures and Registries (44) Clinical Informatics (904) New Methods (901) Research Instruments, Questionnaires, and Tools (540) eHealth Infrastructures (306)

Published on in Vol 23, No 12 (2021): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/28021, first published .
Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism

Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism

Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism

Authors of this article:

Paul Mehta1 Author Orcid Image ;   Jaime Raymond1 Author Orcid Image ;   Moon Kwon Han1 Author Orcid Image ;   Theodore Larson1 Author Orcid Image ;   James D Berry2 Author Orcid Image ;   Sabrina Paganoni2, 3 Author Orcid Image ;   Hiroshi Mitsumoto4 Author Orcid Image ;   Richard Stanley Bedlack5 Author Orcid Image ;   D Kevin Horton1 Author Orcid Image
Article Authors Cited by (5) Tweetations (4) Metrics

Paul Mehta   1 , MD ;   Jaime Raymond   1 , MPH ;   Moon Kwon Han   1 , PhD, MPH, MSc ;   Theodore Larson   1 , MSc ;   James D Berry   2 , MD, MPH ;   Sabrina Paganoni   2, 3 , PhD, MD ;   Hiroshi Mitsumoto   4 , MD ;   Richard Stanley Bedlack   5 , PhD, MD ;   D Kevin Horton   1 , DrPH, MSPH

1 Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, United States

2 Sean M Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, MA, United States

3 Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, United States

4 Department of Neurology, Columbia University College of Physicians and Surgeons, New York City, NY, United States

5 Department of Neurology, Duke University School of Medicine, Durham, NC, United States

Corresponding Author:

  • Paul Mehta, MD
  • Agency for Toxic Substances and Disease Registry
  • Centers for Disease Control and Prevention
  • 4770 Buford Hwy NE
  • Atlanta, GA, 30341
  • United States
  • Phone: 1 770-488-0556
  • Email: pum4@cdc.gov